Chonnam Med J.  2008 Dec;44(3):157-161. 10.4068/cmj.2008.44.3.157.

Therapeutic Effects of 1% Cyclosporin A Eyedrops on Herpetic Stromal Keratitis

• Lee KH
• Park CS
• Juhng SW
• Woo JM
• Park YG
• Yoon KC

• KMID: 2172295
• DOI: http://doi.org/10.4068/cmj.2008.44.3.157

Abstract

We evaluated the therapeutic effects of topical administration of 1% cyclosporin A on herpetic stromal keratitis. Sixteen eyes of 16 patients with non-necrotizing herpetic stromal keratitis were divided into two groups according to the use of topical cyclosporin A and retrospectively reviewed. Symptom duration, visual acuity, stromal haziness, and time to improvement of stromal inflammation were analyzed. Eight eyes of 8 patients were treated with 1% cyclosporin A eyedrops in addition to conventional medication and other 8 patients (8 eyes) with conventional treatment only. There were no differences in pre-treatment symptom duration, visual acuity and stromal haziness between two groups. In cyclosporin A treatment group, visual acuity (p=0.018) and stromal haziness (p=0.034) were significantly improved after treatment. There were no differences in time to improvement of stromal inflammation (p=0.798) and post-treatment visual acuity (p=0.234) between two groups, but post-treatment stromal haziness (p=0.038) significantly improved in cyclosporin A treatment group than in conventional treatment group. Topical cyclosporin A may be effectively used in treatment of herpetic stromal keratitis for reducing stromal haziness.

Keyword

Cyclosporine; Herpes simplex keratitis; Administration, Topical

MeSH Terms

Administration, Topical
Cyclosporine
Eye
Humans
Inflammation
Keratitis
Keratitis, Herpetic
Ophthalmic Solutions
Retrospective Studies
Visual Acuity
Cyclosporine
Ophthalmic Solutions

Figure

• 

  Fig. 1 Patient No. 6. (A) Preoperative anterior segment photograph showing generalized stromal inflammation involving the central cornea. (B) Four months after treatment, the stromal inflammation improved with mild haziness.

Reference

1. Holland EJ, Brilakis HS, Schwartz GS. Krachmer JH, Mannis MJ, Holland EJ, editors. Herpes simplex keratitis. Cornea. 2005. 2nd ed. St. Louis: Mosby;1043–1074.

2. Keadle TL, Morris JL, Pepose JS, Stuart PM. CD4⁺ and CD8⁺ cells are key participants in the development of recurrent herpetic stromal keratitis in mice. Microb Pathog. 2002. 32:255–262.

3. Newell CK, Martin S, Sendele D, Mercadal CM, Rouse BT. Herpes simplex virus-induced stromal keratitis: role of T-lymphocyte subsets in immunopathology. J Virol. 1989. 63:769–775.

4. Thomas J, Gangappa S, Kanangat S, Rouse BT. On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis. J Immunol. 1997. 158:1383–1391.

5. Bauer D, Mrzyk S, van Rooijen N, Steuhl KP, Heiligenhaus A. Macrophage-depletion influences the course of murin HSK-1 keratitis. Curr Eye Res. 2000. 20:45–53.

6. Gangappa S, Deshpande SP, Rouse BT. Bystander activation of CD4 (+) T cells can represent an exclusive means of immunopathology in a virus infection. Eur J Immunol. 1999. 29:3674–3682.

7. Heiligenhaus A, Bauer D, Zheng M, Mrzyk S, Steuhl KP. CD4⁺ T-cell type 1 and type 2 cytokines in the HSK-1 infected cornea. Graefes Arch Clin Exp Ophthalmol. 1999. 237:399–406.

8. Doymaz MZ, Rouse BT. Herpetic stromal keratitis: an immunopathologic disease mediated by CD4+ T lymphocytes. Invest Ophthalmol Vis Sci. 1992. 33:2165–2173.

9. Hendricks RL, Tumpey TM, Finnegan A. IFN-gamma and IL-2 are protective in the skin but pathologic in the corneas of HSV-1-infected mice. J Immunol. 1992. 149:3023–3028.

10. Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol. 2005. 89:1363–1367.

11. Hernández GL, Volpert OV, Iñiguez MA, Lorenzo E, Martinez-Martinez S, Grau R, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med. 2001. 193:607–620.

12. Sall K, Stevenson OD, Mondorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000. 107:631–639.

13. Avunduk AM, Avunduk MC, Erdöl H, Kapicioglu Z, Akyol N. Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica. 2001. 215:290–293.

14. Akpek EK, Dart JK, Watson S, Christen W, Dursun D, Yoo S, et al. A randomized trial of topical cyclosporine 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology. 2004. 111:476–482.

15. Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol. 1999. 237:435–438.

16. Rao SN. Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol. 2006. 141:771–772.

17. Gündüz K, Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res. 1997. 29:405–408.

18. Yoon KC, Heo H, Kang IS, Lee MC, Kim KK, Park SH, et al. Effect of topical cyclosporine A on herpetic stromal keratitis in a mouse model. Cornea. 2008. 27:454–460.

19. Heiligenhaus A, Bauer D, Meller D, Steuhl KP, Tseng SC. Improvement of HSV-1 necrotizing keratitis with amniotic membrane transplantation. Invest Ophthalmol Vis Sci. 2001. 42:1969–1974.

20. Shi W, Chen M, Xie L. Amniotic membrane transplantation combined with antiviral and steroid therapy for herpes necrotizing stromal keratitis. Ophthalmology. 2007. 114:1476–1481.

21. Wilhelmus KR, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB, et al. Herpetic eye disease study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994. 101:1883–1895.

22. Nussenblatt RB, Palestine AG. Cyclosporin: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986. 31:159–169.

23. Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A. Background, immunology, and pharmacology. Cornea. 1990. 9:184–195.

24. Vahlne A, Larsson RA, Horal P, Ahlmén J, Svennerholm B, Gronowitz JS, et al. Inhibition of herpes simplex virus production in vitro by cyclosporine A. Arch Virol. 1992. 122:61–75.

25. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, et al. Cyclosporine suppress hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Trunspl. 2006. 12:51–57.